Literature DB >> 8676168

Simple partial status epilepticus: causes, treatment, and outcome in 47 patients.

F B Scholtes1, W O Renier, H Meinardi.   

Abstract

A retrospective case note review was conducted of 47 patients of 15 years and older who had sustained simple partial status epilepticus (SPSE) in The Netherlands between 1980 and 1987. In 46 patients the type of SPSE was somatomotor (in four adversive), and in one aphasic with visual and auditory hallucinations. SPSE was more common over the age of 50. Six of 27 patients with previous epilepsy had an acute symptomatic cause. In 20 patients without previous epilepsy stroke was the most frequent cause (75%). Outcome was determined by the underlying cause. In one patient the continuing epileptic activity may have caused neuronal damage.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8676168      PMCID: PMC486465          DOI: 10.1136/jnnp.61.1.90

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  11 in total

1.  Unilateral cerebellar damage in focal epilepsy.

Authors:  R Duncan; J Patterson; D M Hadley; I Bone
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-05       Impact factor: 10.154

Review 2.  Focal status epilepticus and epilepsia partialis continua in adults and children.

Authors:  D L Schomer
Journal:  Epilepsia       Date:  1993       Impact factor: 5.864

3.  Prolonged partial complex status epilepticus: EEG and behavioral observations.

Authors:  J Engel; B I Ludwig; M Fetell
Journal:  Neurology       Date:  1978-09       Impact factor: 9.910

Review 4.  Generalized convulsive status epilepticus: pathophysiology and treatment.

Authors:  F B Scholtes; W O Renier; H Meinardi
Journal:  Pharm World Sci       Date:  1993-02-19

5.  [Epilepsia partialis continua of Kozevnikov (author's transl)].

Authors:  O Meienberg; K Karbowski
Journal:  Dtsch Med Wochenschr       Date:  1977-05-27       Impact factor: 0.628

6.  Prolonged focal epilepsy and hypoxemia as a cause of focal brain damage: a case study.

Authors:  D Knopman; G Margolis; A G Reeves
Journal:  Ann Neurol       Date:  1977-02       Impact factor: 10.422

7.  [Epilepsia partialis continua (Kozevnikov epilepsy)].

Authors:  J Löhler; U H Peters
Journal:  Fortschr Neurol Psychiatr Grenzgeb       Date:  1974-04

8.  Malignant migraine: the syndrome of prolonged classical migraine, epilepsia partialis continua, and repeated strokes; a clinically characteristic disorder probably due to mitochondrial encephalopathy.

Authors:  F Andermann; E Lugaresi; G S Dvorkin; P Montagna
Journal:  Funct Neurol       Date:  1986 Oct-Dec

9.  Epilepsia partialis continua.

Authors:  P Juul-Jensen; D Denny-Brown
Journal:  Arch Neurol       Date:  1966-12

10.  Generalized convulsive status epilepticus: causes, therapy, and outcome in 346 patients.

Authors:  F B Scholtes; W O Renier; H Meinardi
Journal:  Epilepsia       Date:  1994 Sep-Oct       Impact factor: 5.864

View more
  5 in total

Review 1.  Stroke-like migraine attacks after radiation therapy (SMART) syndrome-a case series and review.

Authors:  Urvish K Patel; Khush Patel; Preeti Malik; Ahmed Elkady; Nidhi Patel; Abhishek Lunagariya
Journal:  Neurol Sci       Date:  2022-07-13       Impact factor: 3.307

2.  Epidemiology, diagnosis, and management of nonconvulsive status epilepticus: Opening Pandora's box.

Authors:  Raoul Sutter; Stephan Rüegg; Peter W Kaplan
Journal:  Neurol Clin Pract       Date:  2012-12

3.  Nonconvulsive status epilepticus: a diagnostic and therapeutic challenge in the intensive care setting.

Authors:  Martin Holtkamp; Hartmut Meierkord
Journal:  Ther Adv Neurol Disord       Date:  2011-05       Impact factor: 6.570

4.  Treatment of nonconvulsive status epilepticus.

Authors:  Trudy Pang; Frank W Drislane
Journal:  Curr Treat Options Neurol       Date:  2012-08       Impact factor: 3.598

Review 5.  Nonconvulsive status epilepticus in adults - insights into the invisible.

Authors:  Raoul Sutter; Saskia Semmlack; Peter W Kaplan
Journal:  Nat Rev Neurol       Date:  2016-04-11       Impact factor: 42.937

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.